Immunic (NASDAQ:IMUX) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Immunic (NASDAQ:IMUX - Free Report) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

A number of other analysts have also recently commented on the stock. B. Riley reiterated a "buy" rating and issued a $6.00 target price on shares of Immunic in a research note on Wednesday, April 16th. D. Boral Capital reiterated a "buy" rating and set a $17.00 price objective on shares of Immunic in a research note on Wednesday, April 30th. William Blair started coverage on Immunic in a research report on Tuesday, March 25th. They issued an "outperform" rating on the stock. Finally, StockNews.com lowered Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. One research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $13.20.

Immunic Price Performance

Immunic stock traded down $0.04 during midday trading on Thursday, reaching $1.09. The company's stock had a trading volume of 1,205,041 shares, compared to its average volume of 698,567. The stock has a market capitalization of $103.96 million, a P/E ratio of -0.87 and a beta of 1.73. The stock's 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.10. Immunic has a 52-week low of $0.83 and a 52-week high of $2.11.

Institutional Investors Weigh In On Immunic

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC grew its holdings in Immunic by 480.6% during the fourth quarter. Millennium Management LLC now owns 579,683 shares of the company's stock worth $580,000 after acquiring an additional 479,846 shares during the period. Renaissance Technologies LLC grew its stake in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock worth $567,000 after purchasing an additional 177,542 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after purchasing an additional 96,894 shares during the period. Barclays PLC purchased a new position in shares of Immunic during the 4th quarter valued at approximately $84,000. Finally, HB Wealth Management LLC acquired a new position in shares of Immunic in the 4th quarter valued at $81,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.